First Approved Treatment for XLH in Canada that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease.
Kyowa Hakko Kirin President & CEO, Dr. Nobuo Hanai, visits KKI HQ in Galashiels
Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), hosted Dr. Nobuo Hanai, President and Chief Executive Officer of KKI’s parent company, Kyowa Hakko Kirin Co. Ltd., at the company’s head office in Galashiels this week.
